Exhibitor list




94086 Sunnyvale
United States

Viveve leads the way in the burgeoning area of energy-based vaginal therapies with its Viveve® System and treatment. Viveve was born of a passionate commitment to advancing women’s intimate health through clinically-proven innovations. The Viveve treatment is the non-surgical, single-session vaginal treatment proven to safely and comfortably treat vaginal laxity, and/or to improve sexual function, urinary incontinence. The Viveve System uses globally patented, cryogen-cooled monopolar radiofrequency energy (CMRF) technology that delivers energy deep into the submucosa while protecting delicate surface tissue. The Viveve System is available in more than 60 countries around the world.


Product news

  • Viveve Announces FDA Approval to continue Viveve II Study

    Agency determines one-month safety data sufficient in first-stage and grants continued enrollment of up to 100 subjects in second stage of sexual function trial

    ENGLEWOOD, Colo., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to continue enrollment in the company’s multicenter randomized Viveve Treatment of the Vaginal Introitus to EValuate Safety and Efficacy (VIVEVE II) clinical trial to assess the safety and effectiveness of the Viveve® System for the improvement of sexual function in women following vaginal childbirth. The Agency’s approval was based on a determination that the company provided sufficient data to support continued subject enrollment in the trial and that there are no subject protection concerns that preclude continuation of the study.